FrancophonIA/ELRC3.0 huggingface dataset:
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/068
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/068
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/041
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/041
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/010
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/010
English: What Rasilez HCT is
Estonian: Mis ravim on Rasilez HCT
English: NSAIDs may reduce the anti-hypertensive effect of aliskiren.
Estonian: Mittesteroidsed põletikuvastased ained (MSPVA'd) MSPVA'd võivad vähendada aliskireeni antihüpertensiivset toimet.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/080
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/080
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/008
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/008
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PA/ALU/PVC BLISTREID SISALDAVATE MITMIKPAKENDITE VÄLISPAKEND (BLUE BOX'IGA)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/019
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/019
English: The pharmacokinetics of aliskiren are not significantly affected in patients with mild to moderate liver disease.
Estonian: Kerge kuni keskmise raskusega maksahaigus ei mõjuta oluliselt aliskireeni farmakokineetikat.
English: Renal dysfunctionh
Estonian: Neerufunktsiooni häired h
English: • Low level of sodium in the blood
Estonian: • Madal naatriumisisaldus veres
English: MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/08/491/001
English: Posology as substitution therapy
Estonian: Annustamine asendusravina
English: 0.6 ml (10 mg/ml) 1 pre-filled syringe with needle guard + 1 alcohol swab pre-filled injector (glass) 0.6 ml (10 mg/ml) 1 pre-filled injector + 1 alcohol swab
Estonian: 0.6 ml (10 mg/ml) 1 eeltäidetud süstel koos nõelakaitsega + 1 alkoholiga immutatud vatitampoon
English: Strength Pharmaceutical Form
Estonian: Tugevus Ravivorm Manustamistee Pakendi suurus
English: Pack size pre-filled syringe (glass) with needle guard
Estonian: Eeltäidetud süstel (klaas) koos nõelakaitsega
English: The European Commission granted a marketing authorisation valid throughout the EU for Irbesartan BMS to Bristol-Myers Squibb Pharma EEIG on 19 January 2007.
Estonian: Euroopa Komisjon andis Irbesartan BMSi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Bristol-Myers Squibb Pharma EEIG 19. jaanuaril 2007.
English: Irbesartan BMS is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group.
Estonian: Irbesartan BMSi ei soovitata kasutada alla 18 aasta vanustel patsientidel, sest ohutuse ja efektiivsuse andmed selle vanuserühma kohta puuduvad.
English: It is available as white, oval tablets (75, 150 and 300 mg).
Estonian: Seda turustatakse valgete ovaalsete tablettidena (75, 150 või 300 mg).
English: This medicine is the same as Karvea, which is already authorised in the European Union (EU).
Estonian: See ravim on samane Karveaga, millel juba on Euroopa Liidus müügiluba.
English: Irbesartan BMS is taken by mouth, with or without food.
Estonian: Irbesartan BMSi manustatakse suu kaudu, koos toiduga või ilma.
English: The company that makes Karvea has agreed that its scientific data can be used for Irbesartan BMS.
Estonian: Karvea tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Irbesartan BMSi toetuseks.
English: The Committee recommended that Irbesartan BMS be given marketing authorisation.
Estonian: Komitee soovitas anda Irbesartan BMSile müügiloa.
English: For the treatment of kidney disease, Irbesartan BMS was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.
Estonian: Irbesartan BMSi toimet neeruhaiguste ravis uuriti kahes ulatuslikus uuringus, milles osales 2326 patsienti, kes põdesid II tüüpi diabeeti.
English: Irbesartan BMS is used in patients who have essential hypertension (high blood pressure).
Estonian: Irbesartan BMSi kasutatakse patsientidel, kellel on essentsiaalne hüpertensioon (kõrgvererõhutõbi).
English: The active substance in Irbesartan BMS, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Irbesartan BMSi toimeaine irbesartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: Irbesartan BMS should not be used in people who may be hypersensitive (allergic) to irbesartan or any of the other ingredients.
Estonian: Irbesartan BMSi ei tohi kasutada patsiendid, kes võivad olla irbesartaani või Irbesartan BMSi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Irbesartan BMS was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients.
Estonian: 712 patsiendil võrreldi Irbesartan BMSi toimet platseebo (näiva ravimi) toimega ja 823 patsiendil teiste kõrgvererõhuravimite (atenolooli, enalapriili, amlodipiini) toimega.
English: The most common side effects with Irbesartan BMS (seen in more than 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, fatigue (tiredness) and increases in blood creatine kinase levels (an enzyme found in muscles).
Estonian: Irbesartan BMSi kõige sagedamad kõrvalnähud (esinenud ühel kuni kümnel patsiendil sajast) on peapööritus, iiveldus või oksendamine, väsimus ja vere kreatiinkinaasi (lihastes leiduv ensüüm) sisalduse suurenemine.
English: The second study looked at whether Irbesartan BMS increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
Estonian: Teises uuringus jälgiti, kas Irbesartan BMS pikendab aega, mille jooksul patsiendil vere kreatiniinisisaldus (neeruhaiguse marker) kahekordistub või kuni patsient vajab neerusiirdamist või dialüüsi, või aega patsiendi surmani.
English: In addition, more than 1 patient in 100 with type 2 diabetes and kidney disease has the following side effects: hyperkalaemia (high blood potassium levels), orthostatic dizziness (dizziness when standing up), orthostatic hypotension (low blood pressure when standing up) and musculoskeletal (joint) pain.
Estonian: II tüüpi diabeediga ja neeruhaigusega patsientidel esinesid enam kui ühel patsiendil sajast ka järgmised kõrvalnähud: hüperkaleemia (suur kaaliumisisaldus veres) ortostaatiline peapööritus (tekib püsti tõusmisel), luu-lihaskonna (liigeste) valu ja ortostaatiline hüpotensioon (madal vererõhk seismisel).
English: Irbesartan BMS was used for two years or more.
Estonian: Neile manustati Irbesartan BMSi vähemalt kahe aasta jooksul.
English: In this study, Irbesartan BMS was compared with placebo and with amlodipine.
Estonian: Selles uuringus võrreldi Irbesartan BMSi toimet platseebo ja amlodipiini toimega.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IRBESARTAN BMS EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE IRBESARTAN BMS
English: What is Irbesartan BMS?
Estonian: Mis on Irbesartan BMS?
English: Irbesartan BMS is also used to treat kidney disease in patients with hypertension and type 2 diabetes (non-insulin-dependent diabetes).
Estonian: Irbesartan BMSi kasutatakse ka neeruhaiguste raviks hüpertensiooniga ja II tüüpi diabeediga (insuliinisõltumatu suhkurtõvega) patsientidel.
English: Irbesartan BMS is a medicine that contains the active substance irbesartan.
Estonian: Irbesartan BMS ravim, mis sisaldab toimeainena irbesartaani.
English: Irbesartan BMS was originally studied in 11 trials for its effects on blood pressure.
Estonian: Irbesartan BMSi toimet vererõhule uuriti esialgu 11 uuringus.
English: In patients with hypertension and type 2 diabetes, Irbesartan BMS is added to other treatments for hypertension.
Estonian: Kõrgvererõhuga ja II tüüpi diabeediga patsientidel kasutatakse Irbesartan BMSi lisaks teistele kõrgvererõhuravimitele.
English: In the second kidney disease study, Irbesartan BMS reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo.
Estonian: Teises neeruhaiguste uuringus vähendas Irbesartan BMS vere kreatiniinisisalduse kahekordistumise, neerusiirdamise või dialüüsi vajaduse või surma suhtelist riski platseeboga võrreldes 20%.
English: For the full list of all side effects reported with Irbesartan BMS, see the Package Leaflet.
Estonian: Irbesartan BMSi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Irbesartan BMS's benefits are greater than its risks for the treatment of essential hypertension and of renal disease in patients with hypertension and type 2 diabetes mellitus.
Estonian: Inimravimite komitee otsustas, et Irbesartan BMSi kasulikkus essentsiaalse hüpertensiooni ning hüpertensiooniga ja II tüüpi diabeediga neeruhaigete ravis on suurem kui ravimiga kaasnevad riskid.
English: Other information about Irbesartan BMS:
Estonian: Muu teave Irbesartan BMSi kohta
English: Why has Irbesartan BMS been approved?
Estonian: Miks Irbesartan BMS heaks kiideti?
English: In the blood pressure studies, Irbesartan BMS was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Estonian: Vererõhu uuringutes täheldati, et Irbesartan BMS alandab diastoolset vererõhku paremini kui platseebo ning Irbesartan BMSi toime sarnaneb teiste kõrgvererõhuravimite toimega.
English: What is the risk associated with Irbesartan BMS?
Estonian: Mis riskid Irbesartan BMSiga kaasnevad?
English: What benefit has Irbesartan BMS shown during the studies?
Estonian: Milles seisneb uuringute põhjal Irbesartan BMSi kasulikkus?
English: The full EPAR for Irbesartan BMS is available here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Irbesartan BMSi kohta leiate siit.
English: In the first kidney disease study, Irbesartan BMS was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
Estonian: Esimeses neeruhaiguste uuringus oli Irbesartan BMS neerukahjustuse (hinnati valgueritumise alusel) tekkeriski vähendamisel efektiivsem kui platseebo.
English: How is Irbesartan BMS used?
Estonian: Kuidas Irbesartan BMSi kasutatakse?
English: How has Irbesartan BMS been studied?
Estonian: Kuidas Irbesartan BMSi uuriti?
English: How does Irbesartan BMS work?
Estonian: Kuidas Irbesartan BMS toimib?
English: What is Irbesartan BMS used for?
Estonian: Milleks Irbesartan BMSi kasutatakse?
English: Its use in combination with hydrochlorothiazide was also examined in 1,736 patients.
Estonian: Samuti uuriti 1736 patsiendil Irbesartan BMSi koosmõju hüdroklorotiasiidiga.
English: The review was initiated at the request of the European Commission on 7 May 2015, under Article 31 of Directive 2001/83/EC.
Estonian: Läbivaatamist alustati 7. mail 2015 Euroopa Komisjoni nõudel direktiivi 2001/83/EÜ artikli 31 kohaselt.
English: Commission Decision dates: 29/06/2016 (nationally authorised products), 24/06/2016 (Relvar Ellipta, Revinty Ellipta), 04/07/2016 (BiResp Spiromax, DuoResp Spiromax), 06/07/2016 (Budesonide/Formoterol Teva, Vylaer Spiromax).
Estonian: Komisjoni otsuse kuupäevad: 29. juuni 2016 (riikliku müügiloaga ravimid), 24. juuni 2016 (Relvar Ellipta, Revinty Ellipta), 4. juuli 2016 (BiResp Spiromax, DuoResp Spiromax), 6. juuli 2016 (Budesonide/Formoterol Teva, Vylaer Spiromax).
English: Corticosteroid-containing medicines have been authorised in the EU through both central and national approval procedures.
Estonian: Kortikosteroide sisaldavad ravimid on ELis heaks kiidetud nii tsentraalsete kui ka riiklike menetlustega.
English: • Patients who have any concerns should discuss them with their doctor or other healthcare professional.
Estonian: • Mis tahes küsimuste korral peavad patsiendid pöörduma oma arsti või tervishoiutöötaja poole.
English: Corticosteroids, also known as steroids, are anti-inflammatory medicines used for a wide range of conditions.
Estonian: Kortikosteroidid, tuntud ka steroididena, on põletikuvastased ravimid, mida kasutatakse mitme haiguse raviks.
English: • The product information for all medicines of the class will be updated to reflect current knowledge about pneumonia risk.
Estonian: • Kõikide selle rühma ravimite ravimiteave ajakohastatakse, et kajastada olemasolevaid teadmisi pneumoonia riski kohta.
English: • There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.
Estonian: • On tõendeid pneumoonia suurema riski kohta suurema steroidiannuse kasutamisel, kuigi seda ei ole kõigis uuringutes veenvalt tõendatud.
English: They are usually taken using inhalers which either contain a corticosteroid alone or a corticosteroid in combination with another medicine (such as a long-acting beta2 agonist that widens the airways).
Estonian: Tavaliselt manustatakse neid inhalaatoriga, mis sisaldab kas ainult kortikosteroidi või kortikosteroidi koos teise ravimiga (näiteks pikatoimeline beeta2-agonist, mis laiendab bronhe).
English: No clinical trials directly examined the risk of pneumonia with ICS head to head, and only indirect comparison in metaanalyses/systematic reviews or from observational studies is available.
Estonian: Üheski kliinilises uuringus ei käsitletud otseselt pneumoonia riski seost inhaleeritavate kortikosteroidide kasutamisel, mistõttu on olemas ainult metaanalüüsides / süstemaatilistes ülevaadetes või vaatlusuuringutes tehtud kaudsed võrdlused.
English: They are similar to natural hormones normally produced by the adrenal glands (two small glands located above the kidneys).
Estonian: Nad sarnanevad looduslike hormoonidega, mida toodetakse neerupealistes (väikesed näärmed neerude kohal).
English: • The Agency's review included published data from randomised controlled clinical trials and a number of meta-analyses, as well as observational studies.
Estonian: • Euroopa Ravimiameti läbivaatamine hõlmas randomiseeritud kontrollitud kliiniliste uuringute ning mitmete metaanalüüside ja vaatlusuuringute avaldatud andmeid.
English: • Patients should be advised to report any increased breathing difficulties or other symptoms suggestive of infection.
Estonian: • Patsientidele tuleb öelda, et nad teataksid mis tahes suurenenud hingamisraskusest või teistest infektsioonile viitavatest sümptomitest.
English: • Patients need to alert their doctors if they start to get symptoms that suggest they are developing pneumonia, so that it can be identified and treated early.
Estonian: • Patsiendid peavad oma arsti teavitama, kui nad märkavad sümptomeid, mis viitavad pneumoonia tekkele, sest siis on võimalik seda varakult tuvastada ja ravida.
English: The review confirmed the risk of pneumonia with these products, which has been known for many years, and that it is common (can affect between 1 and 10 COPD patients in 100 using these medicines).
Estonian: Läbivaatamine kinnitas pneumoonia riski ja sagedast esinemist nende juba aastaid turustatavate ravimite kasutamisel, samuti seda, et pneumooniat esineb nende ravimite kasutamisel sageli (võib esineda 1-10 kroonilise obstruktiivse kopsuhaigusega patsiendil 100st, kes neid ravimeid tarvitavad).
English: Review finds no differences between products in risk of pneumonia
Estonian: Läbivaatuses ei leitud toodete vahel erinevusi pneumoonia riski seisukohalt
English: Beclomethasone, budesonide, flunisolide, fluticasone propionate and fluticasone furoate are corticosteroids authorised and marketed as inhalation formulations for use in COPD.
Estonian: Beklometasoon, budesoniid, flunisoniid, flutikasoonpropionaat ja flutikasoonfuroaat on müügiloaga kortikosteroidid, mida turustatakse inhaleeritavate preparaatidena kroonilise obstruktiivse kopsuhaiguse raviks.
English: The review was carried out by the Agency's Pharmacovigilance Risk Assessment Committee (PRAC), which recommended that the product information for these medicines should be updated to adequately reflect current knowledge about the risks.
Estonian: Läbivaatuse teostanud ravimiohutuse riskihindamise komitee soovitas ajakohastada nende ravimite ravimiteavet, et piisavalt kajastada olemasolevaid teadmisi nende riskide kohta.
English: In the EU, the available products include the active substances beclomethasone, budesonide, flunisolide, fluticasone furoate or fluticasone propionate.
Estonian: Euroopa Liidus turustatakse ravimeid, mille toimeained on beklometasoon, budesoniid, flunisoliid, flutikasoonfuroaat või flutikasoonpropionaat.
English: These symptoms can be like those of an exacerbation (an episode of worsening COPD) and include fever or chills, increased amounts of mucus (phlegm) or a change in its colour, or worsening of cough or breathing difficulties.
Estonian: Need sümptomid võivad sarnaneda kroonilise obstruktiivse kopsuhaiguse ägenemise sümptomitega ja nendega võivad kaasneda palavik või külmavärinad, suurenenud rögaeritus, röga värvuse muutus, köha süvenemine või hingamisraskus.
English: • It has been known for some time that inhaled corticosteroid medicines increase the risk of pneumonia (infections of the lungs) in patients taking these medicines for the long-term lung disease COPD (chronic obstructive pulmonary disease).
Estonian: • Juba mõnda aega on teada, et inhaleeritavad kortikosteroidid suurendavad pneumoonia (kopsupõletiku) riski patsientidel, kes tarvitavad neid ravimeid pikaajalise kroonilise obstruktiivse kopsuhaiguse raviks.
English: Overall the benefits of inhaled corticosteroid medicines in treating COPD continue to outweigh their risks and there should be no change to the way in which these medicines are used.
Estonian: Üldiselt on inhaleeritavate kortikosteroidide kasulikkus kroonilise obstruktiivse kopsuhaiguse ravis endiselt suurem kui kaasnevad riskid ning ravimite kasutamist ei ole vaja muuta.
English: They should not stop using their inhaler or change the way they use it without consulting their prescriber.
Estonian: Ilma arsti loata ei tohi lõpetada ravimi kasutamist ega muuta selle kasutusviisi.
English: Due to the variability in the clinical data and multiple uncertainties with study methodologies, this does not provide conclusive evidence for intra-class differences in the magnitude of risk.
Estonian: Kliiniliste andmete varieerumist ja uuringumetoodikate ebamäärasust arvestades puuduvad veenvad tõendid, et rühma eri ravimite risk oleks erinev.
English: On 28 April 2016 EMA completed a review of the known risk of pneumonia (lung infection) in patients who take inhaled corticosteroid medicines to treat chronic obstructive pulmonary disease (COPD).
Estonian: 28. aprillil 2016 lõpetas Euroopa Ravimiamet läbivaatamise, mis käsitles pneumoonia (kopsupõletiku) riski patsientidel, kellele manustatakse kroonilise obstruktiivse kopsuhaiguse raviks inhaleeritavaid kortikosteroide.
English: • EMA has reviewed the risk of pneumonia in COPD patients using corticosteroid inhalers and has concluded that this risk applies to all medicines of this class.
Estonian: • Euroopa Ravimiamet vaatas üle pneumoonia riski inhaleeritavaid kortikosteroide kasutavatel kroonilise obstruktiivse kopsuhaigusega patsientidel ja järeldas, et see risk kaasneb kõikide selle rühma ravimitega.
English: Patients with COPD and their doctors should however be alert for signs and symptoms of pneumonia, bearing in mind that the clinical features of pneumonia overlap with those of a worsening (exacerbation) of the underlying disease.
Estonian: Kroonilise obstruktiivse kopsuhaigusega patsiendid ja nende arstid peavad siiski pneumoonia sümptomeid jälgima ja meeles pidama, et pneumoonia kliinilised ilmingud kattuvad olemasoleva haiguse ägenemise sümptomitega.
English: When taken by inhalation they attach to receptors in the airways and cause a reduction in lung inflammation, which makes breathing easier.
Estonian: Inhaleerimisel kinnituvad kortikosteroidid hingamisteedes olevatele retseptoritele ja vähendavad põletikku kopsudes, mis kergendab hingamist.
English: COPD is a long-term disease of the lungs in which the airways and air sacs in the lungs become damaged or blocked, leading to breathing difficulties.
Estonian: Krooniline obstruktiivne kopsuhaigus on pikaajaline kopsuhaigus, mille korral bronhid ja kopsualveoolid on kahjustunud või ummistunud ja see põhjustab hingamisraskusi.
English: Corticosteroid inhalers are widely used in the European Union (EU) to treat COPD and pneumonia is a common side effect of such treatment.
Estonian: Euroopa Liidus kasutatakse kroonilise obstruktiivse kopsuhaiguse raviks laialdaselt kortikosteroidinhalaatoreid ja pneumoonia on sellise ravi sage kõrvalnäht.
English: • Healthcare professionals should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Estonian: • Tervishoiutöötajad peavad olema valvsad pneumoonia võimaliku tekke suhtes kroonilise obstruktiivse kopsuhaigusega patsientidel, sest selle nakkuse kliinilised ilmingud kattuvad kroonilise obstruktiivse kopsuhaiguse ägenemise sümptomitega.
English: The review has been carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Estonian: Teabe on läbi vaadanud inimravimite ohutusprobleemide hindamise eest vastutav ravimiohutuse riskihindamise komitee, kes koostas soovitused.
English: • Corticosteroid inhalers reduce inflammation and swelling in the lungs and so help breathing in patients with COPD.
Estonian: • Inhaleeritavad kortikosteroidid vähendavad kopsudes põletikku ja turset ning kergendavad kroonilise obstruktiivse kopsuhaigusega patsientidel hingamist.
English: The review did not find any conclusive evidence of differences in this risk for different products.
Estonian: Läbivaatamisel ei leitud veenvaid tõendeid eri ravimite kasutamisega kaasneva erineva riski kohta.
English: The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), which adopted the Agency's opinion.
Estonian: Ravimiohutuse riskihindamise komitee soovitused saadeti seejärel inimravimite komiteele, kes võttis vastu Euroopa Ravimiameti arvamuse.
English: The CHMP's opinion was then sent to the European Commission, which issued a final legally-binding decision valid throughout the EU.
Estonian: Inimravimite komitee arvamus edastati Euroopa Komisjonile ja komisjon tegi kogu Euroopa Liidus kehtiva lõpliku otsuse.
English: • Following a review of the available data, EMA has confirmed the risk of pneumonia with inhaled corticosteroids (ICS) in patients with COPD.
Estonian: • Olemasolevate andmete läbivaatamise põhjal kinnitas Euroopa Ravimiamet pneumoonia riski inhaleeritavaid kortikosteroidide kasutavatel kroonilise obstruktiivse kopsuhaigusega patsientidel.
English: There is no conclusive clinical evidence for intra-class differences in the magnitude of the risk among ICS products.
Estonian: Siiski puuduvad veenvad kliinilised tõendid, et see risk oleks inhaleeritavaid kortikosteroide sisaldavatel eri ravimitel erinev.
English: The evidence did not confirm any differences in risk between products.
Estonian: Ei olnud tõendeid, et risk oleks eri preparaatide kasutamisel erinev.
English: Allergic reactions.
Estonian: Allergilised reaktsioonid.
English: 17498 Mesekenhagen Germany or
Estonian: 17498 Mesekenhagen Saksamaa või
English: Xenical with food and drink
Estonian: Xenical koos toidu ja joogiga
English: • Medicines to treat HIV.
Estonian: • HIV raviks kasutatavad ravimid.
English: This is important as using more than one medicine at the same time can strengthen or weaken the effects of the medicines.
Estonian: See on tähtis, kuna rohkem kui ühe ravimi samaaegne kasutamine võib suurendada või vähendada kasutatavate ravimite toimet.